Active
Mainboard

Anthem Biosciences Ltd

Anthem Biosciences Ltd IPO Details

Listing Date

21 Jul 2025

Bid Price

₹540 - ₹570

Lot Size

26 Shares

Minimum Investment

₹14,820 / Lot

Issue Size

₹3395 Cr

Employee Discount

₹50 per share

Schedule

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

14th Jul

tick

Offer End Date

16th Jul

tick

Allotment Date

17th Jul

tick

Refund Initiation

18th Jul

tick

Demat Transfer

18th Jul

tick

Listing Date

21st Jul

About Anthem Biosciences Ltd IPO

Incorporated in 2006, Anthem Biosciences Limited operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities spanning drug discovery, development, and manufacturing. The company caters to a global customer base, including emerging biotech firms and large pharmaceutical companies. Its product portfolio includes fermentation-based active pharmaceutical ingredients (APIs) such as enzymes, probiotics, peptides, biosimilars, and vitamin analogues. As of September 30, 2024, Anthem was involved in 196 projects, including discovery, early and late-phase, and commercial manufacturing projects. The company supported ten commercial molecules from discovery through production.
 

Anthem Biosciences’ CRDMO platform comprises five primary modalities—RNAi, ADC, peptides, lipids, and oligonucleotides—along with four manufacturing capabilities: custom synthesis, flow chemistry, fermentation, and biotransformation. As of March and September 2024, the company served over 550 and 425 customers respectively, across more than 44 countries, including the U.S., Japan, and Europe. The company’s workforce includes 600 professionals from diverse scientific disciplines, and it holds one patent in India, seven internationally, with 24 global patent applications pending.

Anthem Biosciences Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 76.87% 74.69%
Public Group 23.13% 25.31%

Anthem Biosciences Ltd IPO Reservation

QIB Shares Offered 1,18,83,334 (19.95%)
NII (HNI) Shares Offered 89,12,500 (14.96%)
Retail Shares Offered 2,07,95,832 (34.91%)
Anchor Investor Shares Offered 1,78,25,000 (29.93%)
Total Shares Offered 5,95,61,404
Total Shares With Anchor Investor 5,95,61,404

Anthem Biosciences Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 26 ₹14,820
Retail (Max) 13 338 ₹1,92,660
S HNI (Min) 14 364 ₹2,07,480
S HNI (Max) 67 1,742 ₹9,92,940
B HNI (MIN) 68 1,768 ₹10,07,760

Anthem Biosciences Ltd IPO Anchor Portion Size

Bid Date July 11, 2025
Shares Offered 1,78,24,999
Anchor Investment Details 1,016.024943

Anthem Biosciences Ltd IPO registrar

KFin Techologies Ltd
Phone Number +91 40 6716 2222
Email Id einward.ris@kfintech.com
Website www.kfintech.com

Anthem Biosciences Ltd IPO Lead Manager

1. JM Financial Ltd

2. Citigroup Global Markets India Pvt Ltd

3. J.P.Mprgan India Pvt Ltd

4. Nomura Financial Advisors & Securities (India) P

Anthem Biosciences Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹2,409.86 Cr ₹1,924.65 Cr ₹1,740.67 Cr
Reserves and Surplus ₹2,298.05 Cr ₹1,812.84 Cr ₹1,626.57 Cr
Total Borrowing ₹108.95 Cr ₹232.52 Cr ₹125.06 Cr

Anthem Biosciences Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid Subscription (Times)
Qualified Institutional Buyers (QIBs) 1,25,43,518 2,29,10,95,976 182.6518
Non Institutional Investors (NIIs) 94,07,639 39,84,69,578 42.356
Retail Individual Investors (RIIs) 2,19,51,158 12,38,47,828 5.642
Total 4,40,70,682 2,81,45,24,128 63.8639

Strength of Anthem Biosciences Ltd

  • The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.
  • Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
  • Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,
  • Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.

Risks Involved

  • Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company business.
  • Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons that are not within its control.
  • Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialized molecules, may have an adverse impact on its business, financial condition, results of operations and prospects.
  • The company is subject to rapid advancements in technology which requires continuous investments. Its may not be successful in developing new technologies and improving its existing technologies to maintain the company competitive position. Any such failures to develop technologies may have a material and adverse impact on its business, financial condition and results of operations.
  • The company is subject to extensive government regulations, and if its fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate the company business, results of operations and cash flows may be adversely affected.
  • The company depends on certain key customers for a significant portion of its revenues (its top 5 and top 10 customers contributed to 70.92% and 77.33%, respectively, of its revenue from operations in Fiscal 2025). Any inability to retain the company key customers or decrease in revenues from any of its key customers could negatively affect the company business and results of operations.
  • The company is dependent on its arrangements with DavosPharma, the affiliate of one of its Shareholders and also a Selling Shareholder, for the company business and marketing activities in the United States.
  • The company faces the risk of losing manufacturing revenue from services supplied to innovator pharmaceutical companies after the expiry of their patent protection period, which may lead to the availability of alternative formulations at a lower cost.
  • The company is highly dependent on its skilled workforce, in particular its R&D team, for the company day-to-day operations. The loss of, or its inability to attract or retain such persons may lead to knowledge loss and have a material adverse effect on the company business performance.
  • The Offer Price of its Equity Shares, the company price-to-earnings ratio, its enterprise value to EBITDA ratio and the company market capitalisation to total revenue from operations ratio may not be indicative of the trading price of its Equity Shares upon listing on the Stock Exchanges subsequent to the Offer and, as a result, you may lose a significant part or all of your investment.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Anthem Biosciences IPO

  • The global pharmaceutical industry is anticipated to reach a value of USD 2,076.0 billion by 2029, as per the F&S Report.

  • Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) are increasingly combining their offerings.

  • This shift is leading to the development of integrated Contract Research, Development and Manufacturing Organization (CRDMO) business models.

  • The Indian CRDMO industry is expected to expand at a compound annual growth rate (CAGR) of 13.4% between 2024 and 2029.

  • By 2029, the Indian CRDMO market is estimated to reach a value of USD 15.4 billion.

  • The projected growth rate for India exceeds the global industry CAGR of 9.1% and several other regions.

  • Despite this trend, pharmaceutical companies continue to face challenges.

  • Key concerns include pricing pressures, a limited success rate of experimental compounds reaching commercialisation, and rising regulatory requirements.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Anthem Biosciences IPO.

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Striders Impex Limited IPO
Bidding Period
26th Feb 2026 - 3rd Mar 2026
Price Range
₹71.0 - 72.0
IPO Size
₹36,29,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amir Chand Jagadish Kumar Exports Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
APPL Containers Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ardee Engineering Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Closing Today
Bidding Period
20th Feb 2026 - 2nd Feb 2026
Price Range
₹75.0 - 79.0
IPO Size
₹1,65,00,00,000
MANILAM INDUSTRIES INDIA LIMITED IPO
Closing Today
Bidding Period
20th Feb 2026 - 2nd Feb 2026
Price Range
₹65.0 - 69.0
IPO Size
₹40,00,00,000
FRACTAL INDUSTRIES LIMITED IPO
Bidding Period
16th Feb 2026 - 2nd Feb 2026
Price Range
₹205.0 - 216.0
IPO Size
₹49,00,00,000
MARUSHIKA TECHNOLOGY LIMITED IPO
Bidding Period
12th Feb 2026 - 2nd Feb 2026
Price Range
₹111.0 - 117.0
IPO Size
₹27,00,00,000
FRACTAL ANALYTICS LIMITED IPO
Bidding Period
9th Feb 2026 - 2nd Feb 2026
Price Range
₹857.0 - 900.0
IPO Size
₹28,34,00,00,000
AYE FINANCE LIMITED IPO
Bidding Period
9th Feb 2026 - 2nd Feb 2026
Price Range
₹122.0 - 129.0
IPO Size
₹10,10,00,00,000
BIOPOL CHEMICALS LIMITED IPO
Bidding Period
6th Feb 2026 - 2nd Feb 2026
Price Range
₹102.0 - 108.0
IPO Size
₹31,00,00,000
PAN HR SOLUTION LIMITED IPO
Bidding Period
6th Feb 2026 - 2nd Feb 2026
Price Range
₹74.0 - 78.0
IPO Size
₹17,00,00,000
NFP SAMPOORNA FOODS LIMITED IPO
Bidding Period
4th Feb 2026 - 2nd Feb 2026
Price Range
₹52.0 - 55.0
IPO Size
₹25,00,00,000
BRANDMAN RETAIL LIMITED IPO
Bidding Period
4th Feb 2026 - 2nd Feb 2026
Price Range
₹167.0 - 176.0
IPO Size
₹86,00,00,000
GROVER JEWELLS LIMITED IPO
Bidding Period
4th Feb 2026 - 2nd Feb 2026
Price Range
₹83.0 - 88.0
IPO Size
₹34,00,00,000
C K K RETAIL MART LIMITED IPO
Bidding Period
30th Jan 2026 - 2nd Feb 2026
Price Range
₹155.0 - 163.0
IPO Size
₹88,00,00,000
ACCRETION NUTRAVEDA LIMITED IPO
Bidding Period
28th Jan 2026 - 1st Jan 2026
Price Range
₹122.0 - 129.0
IPO Size
₹25,00,00,000
MSAFE EQUIPMENTS LIMITED IPO
Bidding Period
28th Jan 2026 - 1st Jan 2026
Price Range
₹116.0 - 123.0
IPO Size
₹66,00,00,000
KANISHK ALUMINIUM INDIA LIMITED IPO
Bidding Period
28th Jan 2026 - 1st Jan 2026
Price Range
₹73.0 - 73.0
IPO Size
₹29,00,00,000
KASTURI METAL COMPOSITE LIMITED IPO
Bidding Period
27th Jan 2026 - 1st Jan 2026
Price Range
₹61.0 - 64.0
IPO Size
₹18,00,00,000
HANNAH JOSEPH HOSPITAL LIMITED IPO
Bidding Period
22nd Jan 2026 - 1st Jan 2026
Price Range
₹67.0 - 70.0
IPO Size
₹42,00,00,000
SHAYONA ENGINEERING LIMITED IPO
Bidding Period
22nd Jan 2026 - 1st Jan 2026
Price Range
₹140.0 - 144.0
IPO Size
₹15,00,00,000
KRM AYURVEDA LIMITED IPO
Bidding Period
21st Jan 2026 - 1st Jan 2026
Price Range
₹128.0 - 135.0
IPO Size
₹77,00,00,000
SHADOWFAX TECHNOLOGIES LIMITED IPO
Bidding Period
20th Jan 2026 - 1st Jan 2026
Price Range
₹118.0 - 124.0
IPO Size
₹19,07,00,00,000
  • All
  • MainBoard
  • SME
MARUSHIKA TECHNOLOGY LIMITED IPO
Issue Prize
117.00
Listing Day Close
114.00(-2.56%)
FRACTAL ANALYTICS LIMITED IPO
Issue Prize
900.00
Listing Day Close
847.40(-5.89%)
AYE FINANCE LIMITED IPO
Issue Prize
129.00
Listing Day Close
128.90(0.00%)
BIOPOL CHEMICALS LIMITED IPO
Issue Prize
108.00
Listing Day Close
105.50(-1.85%)
PAN HR SOLUTION LIMITED IPO
Issue Prize
78.00
Listing Day Close
78.01(0.00%)
BRANDMAN RETAIL LIMITED IPO
Issue Prize
176.00
Listing Day Close
192.15(9.09%)
GROVER JEWELLS LIMITED IPO
Issue Prize
88.00
Listing Day Close
100.80(14.77%)
C K K RETAIL MART LIMITED IPO
Issue Prize
163.00
Listing Day Close
171.15(4.91%)
ACCRETION NUTRAVEDA LIMITED IPO
Issue Prize
129.00
Listing Day Close
191.20(48.06%)
MSAFE EQUIPMENTS LIMITED IPO
Issue Prize
123.00
Listing Day Close
150.30(21.95%)
KANISHK ALUMINIUM INDIA LIMITED IPO
Issue Prize
73.00
Listing Day Close
55.48(-24.66%)
KASTURI METAL COMPOSITE LIMITED IPO
Issue Prize
64.00
Listing Day Close
63.16(-1.56%)
HANNAH JOSEPH HOSPITAL LIMITED IPO
Issue Prize
70.00
Listing Day Close
68.25(-2.86%)
SHAYONA ENGINEERING LIMITED IPO
Issue Prize
144.00
Listing Day Close
151.00(4.86%)
KRM AYURVEDA LIMITED IPO
Issue Prize
135.00
Listing Day Close
180.70(34.07%)
SHADOWFAX TECHNOLOGIES LIMITED IPO
Issue Prize
124.00
Listing Day Close
109.90(-11.29%)
DIGILOGIC SYSTEMS LIMITED IPO
Issue Prize
104.00
Listing Day Close
79.05(-24.04%)
ARITAS VINYL LIMITED IPO
Issue Prize
47.00
Listing Day Close
44.65(-4.26%)
ARMOUR SECURITY INDIA LIMITED IPO
Issue Prize
57.00
Listing Day Close
43.35(-24.56%)
AM
AMAGI MEDIA LABS LIMITED IPO
Issue Prize
361.00
Listing Day Close
348.00(-3.60%)

Frequently Asked Questions

What is Anthem Biosciences Ltd IPO?

Answer Field

Anthem Biosciences Ltd IPO is a Mainboard IPO of 5,95,61,404 equity shares of a face value of ₹2 aggregating up to ₹3395 Crores. The issue is priced at ₹540 to ₹570 per share. The minimum order quantity is 26 Shares. The IPO opens on July 14, 2025, and closes on July 16, 2025. KFin Techologies Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Anthem Biosciences Ltd IPO will open?

Answer Field

The Anthem Biosciences Ltd IPO opens on July 14, 2025 and closes on July 16, 2025.

What is the lot size of Anthem Biosciences Ltd?

Answer Field

Anthem Biosciences Ltd lot size is 26 shares, and the minimum amount required is ₹14,820.

How to apply for Anthem Biosciences Ltd IPO?

Answer Field

You can apply in Anthem Biosciences Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Anthem Biosciences Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Anthem Biosciences Ltd IPO will be done on July 17, 2025, and the allotted shares will be credited to your demat account by July 18, 2025.

When is Anthem Biosciences Ltd IPO listing date?

Answer Field

The Anthem Biosciences Ltd listing date is July 21, 2025.

Who is the registrar of Anthem Biosciences Ltd IPO?

Answer Field

The registrar of Anthem Biosciences Ltd IPO is KFin Techologies Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

JM Financial Ltd,Citigroup Global Markets India Pvt Ltd,J.P.Mprgan India Pvt Ltd,Nomura Financial Advisors & Securities (India) P will be the book-running lead manager of this IPO.

What is the fresh issue of Anthem Biosciences Ltd IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Anthem Biosciences Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 26 shares and ₹14,820 amount.

How can I approve the UPI mandate request for Anthem Biosciences Ltd IPO?

Answer Field

To apply for Anthem Biosciences Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Anthem Biosciences Ltd?

Answer Field

The price of each Anthem Biosciences Ltd share will be ranging in between ₹540 to ₹570 per share.

What is the cut-off time for the UPI mandate for Anthem Biosciences Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, July 16, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|